Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Codexis Inc Market Cap
From what 7 stock analysts predict, the share price for Codexis Inc (CDXS) might increase by 26.4% in the next year. This is based on a 12-month average estimation for CDXS. Price targets go from $3 to $11. The majority of stock analysts believe CDXS is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
CDXS is a stock in Healthcare which has been forecasted to be worth $7.16667 as an average. On the higher end, the forecast price is $11 USD by Brandon Couillard from Jefferies and on the lower end CDXS is forecasted to be $3 by from Piper Sandler.
These are the latest 20 analyst ratings of CDXS.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Kristen Kluska Cantor Fitzgerald | Overweight | $11 | Reiterates | Nov 22, 2024 |
| Kristen Kluska Cantor Fitzgerald | Overweight | $11 | Reiterates | Nov 15, 2024 |
| Robert Wasserman Benchmark | Hold | Reiterates | Nov 4, 2024 | |
| Kristen Kluska Cantor Fitzgerald | Overweight | $11 | Reiterates | Sep 20, 2024 |
| Kristen Kluska Cantor Fitzgerald | Overweight | $11 | Reiterates | Aug 29, 2024 |
| Robert Wasserman Benchmark | Hold | Downgrade | Aug 19, 2024 | |
| Kristen Kluska Cantor Fitzgerald | Overweight | $11 | Reiterates | Aug 9, 2024 |
| Kristen Kluska Cantor Fitzgerald | Overweight | $11 | Initiates | May 30, 2024 |
| Robert Wasserman Benchmark | Buy | $9 | Reiterates | May 3, 2024 |
| Robert Wasserman Benchmark | Buy | $9 | Upgrade | Feb 29, 2024 |
| Robert Wasserman Benchmark | Hold | Downgrade | Nov 7, 2023 | |
| Kashy Harrison Piper Sandler | Overweight | $10 | Maintains | Nov 6, 2023 |
| Robert Wasserman Benchmark | Buy | $9 | Reiterates | Sep 1, 2023 |
Stifel | Buy | Maintains | Aug 14, 2023 | |
Stephens & Co. | Overweight | Reiterates | Jul 21, 2023 | |
| Robert Wasserman Benchmark | Buy | $9 | Maintains | May 9, 2023 |
| Swayampakula Ramakanth HC Wainwright & Co. | Neutral | Downgrade | May 9, 2023 | |
| Kashy Harrison Piper Sandler | Overweight | $14 | Maintains | Apr 17, 2023 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $9 | Maintains | Feb 27, 2023 |
| Do Kim Piper Sandler | Overweight | $23 | Maintains | Jan 19, 2023 |
When did it IPO
2010
Staff Count
174
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Stephen George Dilly MBBS, Ph.D.
Market Cap
$461.4M
In 2023, CDXS generated $70.1M in revenue, which was a decrease of -49.39% from the previous year. This can be seen as a signal that CDXS's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Fri, 06 Dec 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Codexis, Inc. announced equity grants to five new employees, totaling 168,400 stock options and 39,750 restricted stock units, approved by its Compensation Committee.
Why It Matters - Equity grants to new employees often signal company growth and confidence in future performance, potentially impacting stock value and investor sentiment positively.
Tue, 19 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Codexis, Inc. (NASDAQ: CDXS) will attend the Piper Sandler 36th Annual Healthcare Conference from December 3-5, 2024, in New York, focusing on enzymatic solutions for therapeutics manufacturing.
Why It Matters - Codexis's attendance at a major healthcare conference may signal potential partnerships, innovations, or investments, influencing market perception and stock performance.
Thu, 14 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Codexis, Inc. (NASDAQ: CDXS) presented four synthesis routes for approved siRNA therapy and showcased superior double-stranded RNA ligases at TIDES Europe. A conference call is scheduled for 4:30 PM EST.
Why It Matters - Codexis' breakthrough in siRNA synthesis and superior enzyme performance could enhance its market position, potentially boosting revenue and investor confidence in upcoming developments.
Mon, 11 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Codexis, Inc. will present four siRNA synthesis routes and a comparative study of its RNA ligase at TIDES Europe, Nov. 12-14, 2024, and will hold a conference call on Nov. 14 to discuss data.
Why It Matters - Codexis's presentations on siRNA synthesis highlight its innovation in therapeutics manufacturing, potentially boosting investor confidence and influencing stock performance.
Tue, 12 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Codexis, Inc. (NASDAQ: CDXS) has appointed Raymond De Vré, PhD, to its Board of Directors, enhancing its leadership in enzymatic solutions for therapeutics manufacturing.
Why It Matters - Raymond De Vré's appointment could enhance Codexis's strategic direction and governance, potentially impacting innovation and growth prospects, influencing investor confidence and stock performance.
Mon, 04 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Codexis, Inc. (NASDAQ: CDXS) will participate in four upcoming investor conferences, highlighting its role in enzymatic solutions for therapeutics manufacturing.
Why It Matters - Codexis's participation in multiple investor conferences signals potential growth and engagement, which may attract investor interest and affect stock performance positively.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
